New trends in the treatment of immune thrombocytopenia during the COVID-19 pandemic

Léčba ITP v době COVID-19

Abstract

Treatment of immune thrombocytopenia (ITP) has undergone some changes during the COVID-19 pandemic. In addition to traditional first-line therapy, the thrombopoetin receptor agonists therapy and combination of immunosuppressants have achieved a stronger position in recent years. Nevertheless, there are still refractory cases that require a more aggressive approach or application of the new targeted drugs outside the approved indications or studies. The COVID-19 pandemic itself and the subsequent boom in vaccination are often the only traceable cause of new cases of ITP diagnosed in previous two years.